Business Wire

SITA and LiveAction Partner to Ensure Complete Visibility Across Aviation Networks

Share

SITA, the leading IT provider to the air transport industry, and LiveAction, the leader in network performance management, today announced the availability of a new reporting solution that gives customers complete visibility and service assurance across WAN and SD-WAN deployments. Based on LiveAction’s LiveSP, the SITA SDN Reporting Platform is available as part of SITA Service Management Assurance, an industry-leading Service Management offering that helps customers achieve maximum value from SITA subscribed services.

LiveAction provides end-to-end visibility into network and application performance from a centralized, single pane of glass dashboard. The platform unifies networking data by collecting, analyzing and reporting on diverse network telemetry datasets, allowing organizations to optimize network, application and end-user performance. This helps network operations teams improve visibility across the entire hybrid network and track network usage, application performance, SD-WAN performance, COS information, cloud traffic usage, network latency and much more. Designed for service providers, LiveSP enables SITA to provide enhanced customer visibility and business insights for SITA Connect services – offering secure, reliable, and flexible network connectivity solutions that deliver ever-improving passenger experiences globally.

“Partnering with LiveAction has helped us develop a world-class service management offering for software-defined networking (SDN), including the co-development of unique reporting features that bring real value to our customers,” said Martin Smillie, Vice-President of Communications and Data Exchange at SITA. “The out-of-the-box integration with existing SDN vendors has reduced time to market with a robust and comprehensive solution.”

With many large airline customers already onboarded in the platform, SITA will be further enhancing the offering by integrating LiveAction LiveWire, a network packet capture solution. This will enable customers to extend network visibility and application troubleshooting and conduct deep forensic analysis if needed.

“Today’s networks are complex and changing rapidly. Having complete visibility into network and application performance is critical to delivering high-performance network services and being able to troubleshoot issues that arise,” said Stephen Stuut, Chief Executive Officer at LiveAction. “We’re excited to be working with SITA to help ensure their customers have world class connectivity and performance across global networks. This has been a complete team effort on both sides.”

For more information on SITA Service Management Assurance and the new reporting solution with LiveSP go to SITA | SITA Service Management.

About SITA

SITA is the air transport industry's IT provider, delivering solutions for airlines, airports, aircraft and governments. Our technology powers more seamless, safe and sustainable air travel. For further information, go to www.sita.aero.

About LiveAction

LiveAction provides end-to-end visibility into network and application performance from a single pane of glass. This gives enterprises confidence that the network is meeting business objectives, offers IT administrators full visibility for better decision making, and reduces the overall cost of operations. By unifying and simplifying the collection, correlation and presentation of network and application data, LiveAction empowers network professionals to proactively and quickly identify, troubleshoot and resolve issues across complex networks. Learn more at https://www.liveaction.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Justin Hall
Voxus PR
jhall@voxuspr.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye